S100A13在乳腺癌组织中的表达及临床意义(1)
【摘要】 目的：探讨S100A13在乳腺良恶性组织中的表达以及临床意义。方法：选取2015年9月-2017年9月来自佳木斯大学附属第一医院收治的乳腺疾病患者108例作为研究对象，其中68例乳腺癌患者为乳腺癌组，40例乳腺纤维腺瘤患者为乳腺纤维腺瘤组。通过免疫组化染色SP法检测S100A13在两组中的表达结果。结果：在乳腺癌组中有39例S100A13表达阳性，阳性率为57.35%，在乳腺纤维瘤组中有15例S100A13表达阳性，阳性率为37.50%，S100A13在两组中的表达情况比较，差异有统计学意义(字2=3.971，P<0.05)。S100A13的阳性表达率在乳腺癌患者的年龄和肿块大小上比较，差异均无统计学意义(P>0.05)。而S100A13的阳性表达率随乳腺癌的临床分期升高而升高，Ⅲ+Ⅳ期乳腺癌患者的S100A13阳性表达率为78.57%，明显高于Ⅰ+Ⅱ期的52.50%，差异有统计学意义(P<0.05)；乳腺癌淋巴结转移患者的S100A13阳性表达率为63.04%，明显高于无淋巴结转移的36.36%，差异有统计学意义(P<0.05)。结论：关于S100A13的表达与乳腺癌的发生发展关系研究较少，本研究表明S100A13可能成为判断乳腺肿物良恶性的又一有价值的辅助检查指标，并有可能为乳腺癌的预后提供有意义的参考，同时成为新的治疗靶点。
, 百拇医药
【关键词】 乳腺癌； S100A13； 免疫組化
【Abstract】 Objective：To investigate the expression of S100A13 in benign and malignant breast tissues and its clinical significance.Method：A total of 118 patients with breast disease in the First Affiliated Hospital of Jiamusi University from September 2015 to September 2017 were selected as the study objects.68 cases breast cancer patients were set up as breast cancer group and 40 cases breast fibroadenoma patients were set up as breast fibroadenoma group.The expression of S100A13 in two groups was detected by immunohistochemical SP method.Result：In breast cancer group，39 cases were positive for S100A13，the positive rate was 57.35%；and in breast fibroadenoma group，15 cases were positive，the positive rate was 37.50%，the expression of S100A13 between the two groups was compared，the difference was statistically significant(字2=3.971，P<0.05).The positive expression rates of S100A13 were not significantly different in age and tumor size of breast cancer patients(P>0.05).The positive expression rate of S100A13 increased with the clinical stage of breast cancer，the positive expression rate of S100A13 in stage Ⅲ and Ⅳ breast cancer was 78.57%，which was significantly higher than 52.50% of stage Ⅰ and Ⅱ，the difference was statistically significant (P<0.05).The positive rate of S100A13 in patients with lymph node metastasis from breast cancer was 63.04%，which was significantly higher than 36.36% without lymph node metastasis，the difference was statistically significant (P<0.05).Conclusion：There is little research on the relationship between the expression of S100A13 and the occurrence and development of breast cancer.This study shows that S100A13 may be another valuable auxiliary test to judge benign and malignant breast tumor and may provide a meaningful reference of prognosis for breast cancer，while becoming a new therapeutic target.
【Key words】 Breast cancer； S100A13； Immunohistochemistry, 百拇医药(刘应红 田寅 胡少军)
, 百拇医药
【关键词】 乳腺癌； S100A13； 免疫組化
【Abstract】 Objective：To investigate the expression of S100A13 in benign and malignant breast tissues and its clinical significance.Method：A total of 118 patients with breast disease in the First Affiliated Hospital of Jiamusi University from September 2015 to September 2017 were selected as the study objects.68 cases breast cancer patients were set up as breast cancer group and 40 cases breast fibroadenoma patients were set up as breast fibroadenoma group.The expression of S100A13 in two groups was detected by immunohistochemical SP method.Result：In breast cancer group，39 cases were positive for S100A13，the positive rate was 57.35%；and in breast fibroadenoma group，15 cases were positive，the positive rate was 37.50%，the expression of S100A13 between the two groups was compared，the difference was statistically significant(字2=3.971，P<0.05).The positive expression rates of S100A13 were not significantly different in age and tumor size of breast cancer patients(P>0.05).The positive expression rate of S100A13 increased with the clinical stage of breast cancer，the positive expression rate of S100A13 in stage Ⅲ and Ⅳ breast cancer was 78.57%，which was significantly higher than 52.50% of stage Ⅰ and Ⅱ，the difference was statistically significant (P<0.05).The positive rate of S100A13 in patients with lymph node metastasis from breast cancer was 63.04%，which was significantly higher than 36.36% without lymph node metastasis，the difference was statistically significant (P<0.05).Conclusion：There is little research on the relationship between the expression of S100A13 and the occurrence and development of breast cancer.This study shows that S100A13 may be another valuable auxiliary test to judge benign and malignant breast tumor and may provide a meaningful reference of prognosis for breast cancer，while becoming a new therapeutic target.
【Key words】 Breast cancer； S100A13； Immunohistochemistry, 百拇医药(刘应红 田寅 胡少军)
参见：首页 > 医疗版 > 疾病专题 > 普通外科 > 乳腺癌